Current Drug Targets

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back Subscribe
Translate in Chinese
Research Article

Novel Glitazones Protect Rotenone-induced Parkinsonism in Mouse Models by Targeting PGC1α

Author(s): Shreyas Ayachitorcid of author, Ganavi Bethanagere Rameshaorcid of author, Kamsagara Linganna Krishna*orcid of author, Ujwal Reddy Pesaladinneorcid of author, Prashanthakumar Bommenahalli Ravanappaorcid of author, Divya Durai Babuorcid of author, Seema Mehdiorcid of author and Suman Pathakauthors OrcID

Volume 26, Issue 14, 2025

Published on: 09 September, 2025

Page: [1025 - 1044] Pages: 20

DOI: 10.2174/0113894501395776250903093531

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Introduction: Parkinson’s disease (PD) is a persistent neurodegenerative condition marked by rising global rates of disability and mortality, warranting the need for new treatment options. The present investigation evaluated the protective effects of novel glitazones C7 and C25 against rotenone-induced PD in a mouse model.

Methods: Molecular docking using Discovery Studio and molecular dynamics simulations were employed to evaluate the binding ability of C7 and C25 to the PGC-1α target protein. Pharmacokinetic evaluations of C7 and C25 were performed against the standard pioglitazone in the rats model, and acute toxicity assessments were conducted following OECD guidelines 423. The neuroprotective effects of C7 were tested in a rotenone-induced mouse model of PD at doses of 10, 20, and 30 mg/kg body weight. Behavioral studies, including locomotor activity, grip strength, and catalepsy, as well as biochemical analyses such as endogenous antioxidant levels and AChE levels, were assessed.

Results: The novel compound C7 demonstrated good binding and simulation at the PGC-1α target protein. The kinetic profile of C7 was found to be good when compared to C25. Both the novel glitazones were safe at 300 mg/kg body weight when tested for oral acute toxicity. The novel compound C7 effectively alleviated symptoms related to rotenone-induced PD, demonstrating its promise as a therapeutic candidate.

Discussion: In the rotenone-induced mouse model, compound C7 exhibited a promising anti-PD effect by attenuating oxidative stress and increasing muscular activity, which merits further investigations.

Conclusion: Additional research using various induction models, along with further investigation of cellular and molecular markers in larger animal studies, is needed to validate these findings.

Keywords: Glitazones, thiazolidinedione, rotenone, neuroprotection, animal model, PGC-1α.

Graphical Abstract

[1]
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet 2021; 397(10291): 2284-303.
[http://dx.doi.org/10.1016/S0140-6736(21)00218-X] [PMID: 33848468]
[2]
Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 2021; 20(5): 385-97.
[http://dx.doi.org/10.1016/S1474-4422(21)00030-2] [PMID: 33894193]
[3]
Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson’s disease. Lancet 2024; 403(10423): 283-92.
[http://dx.doi.org/10.1016/S0140-6736(23)01419-8] [PMID: 38245248]
[4]
Ball N, Teo WP, Chandra S, Chapman J. Parkinson’s disease and the environment. Front Neurol 2019; 10: 218.
[http://dx.doi.org/10.3389/fneur.2019.00218] [PMID: 30941085]
[5]
Chia SJ, Tan EK, Chao YX. Historical perspective: Models of Parkinson’s disease. Int J Mol Sci 2020; 21(7): 2464.
[http://dx.doi.org/10.3390/ijms21072464] [PMID: 32252301]
[6]
Zubelzu M, Morera-Herreras T, Irastorza G, Gómez-Esteban JC, Murueta-Goyena A. Plasma and serum alpha-synuclein as a biomarker in Parkinson’s disease: A meta-analysis. Parkinsonism Relat Disord 2022; 99: 107-15.
[http://dx.doi.org/10.1016/j.parkreldis.2022.06.001] [PMID: 35717321]
[7]
Zheng Y, Li S, Yang C, Yu Z, Jiang Y, Feng T. Comparison of biospecimens for α-synuclein seed amplification assays in Parkinson’s disease: A systematic review and network meta-analysis. Eur J Neurol 2023; 30(12): 3949-67.
[http://dx.doi.org/10.1111/ene.16041] [PMID: 37573472]
[8]
Basellini MJ, Kothuis JM, Comincini A, Pezzoli G, Cappelletti G, Mazzetti S. Pathological pathways and alpha-synuclein in parkinson’s disease: A view from the periphery. Front Biosci 2023; 28(2): 33.
[http://dx.doi.org/10.31083/j.fbl2802033] [PMID: 36866559]
[9]
Murphy J, McKernan DP. The effect of aggregated alpha synuclein on synaptic and axonal proteins in Parkinson’s disease—A systematic review. Biomolecules 2022; 12(9): 1199.
[http://dx.doi.org/10.3390/biom12091199] [PMID: 36139038]
[10]
Ganguly U, Singh S, Pal S, et al. Alpha-synuclein as a biomarker of Parkinson’s disease: Good, but not good enough. Front Aging Neurosci 2021; 13: 702639.
[http://dx.doi.org/10.3389/fnagi.2021.702639] [PMID: 34305577]
[11]
Srinivasan E, Chandrasekhar G, Chandrasekar P, et al. Alpha-synuclein aggregation in Parkinson’s disease. Front Med 2021; 8: 736978.
[http://dx.doi.org/10.3389/fmed.2021.736978] [PMID: 34733860]
[12]
Emin D, Zhang YP, Lobanova E, et al. Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease. Nat Commun 2022; 13(1): 5512.
[http://dx.doi.org/10.1038/s41467-022-33252-6] [PMID: 36127374]
[13]
Haque ME, Akther M, Azam S, et al. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson’s disease. Br J Pharmacol 2022; 179(1): 23-45.
[http://dx.doi.org/10.1111/bph.15684] [PMID: 34528272]
[14]
Kim MS, Ra EA, Kweon SH, et al. Advanced human iPSC-based preclinical model for Parkinson’s disease with optogenetic alpha-synuclein aggregation. Cell Stem Cell 2023; 30(7): 973-986.e11.
[http://dx.doi.org/10.1016/j.stem.2023.05.015] [PMID: 37339636]
[15]
Wang R, Ren H, Kaznacheyeva E, Lu X, Wang G. Association of glial activation and α-synuclein pathology in Parkinson’s disease. Neurosci Bull 2023; 39(3): 479-90.
[http://dx.doi.org/10.1007/s12264-022-00957-z] [PMID: 36229715]
[16]
Rouaud T, Corbillé AG, Leclair-Visonneau L, et al. Pathophysiology of Parkinson’s disease: Mitochondria, alpha-synuclein and much more…. Rev Neurol 2021; 177(3): 260-71.
[http://dx.doi.org/10.1016/j.neurol.2020.07.016] [PMID: 33032797]
[17]
Li W, Fu Y, Halliday GM, Sue CM. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson’s disease. Front Cell Dev Biol 2021; 9: 612476.
[http://dx.doi.org/10.3389/fcell.2021.612476] [PMID: 34295884]
[18]
van der Gaag BL, Deshayes NAC, Breve JJP, et al. Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia. Acta Neuropathol 2024; 147(1): 14.
[http://dx.doi.org/10.1007/s00401-023-02657-y] [PMID: 38198008]
[19]
Zhang S, Liu YQ, Jia C, et al. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson’s disease. Proc Natl Acad Sci USA 2021; 118(26): 2011196118.
[http://dx.doi.org/10.1073/pnas.2011196118] [PMID: 34172566]
[20]
Prymaczok NC, De Francesco PN, Mazzetti S, et al. Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease. NPJ Parkinsons Dis 2024; 10(1): 10.
[http://dx.doi.org/10.1038/s41531-023-00618-6] [PMID: 38184623]
[21]
Vankayala SL, Warrensford LC, Pittman AR, et al. CIFDOCK : A novel CHARMM -based flexible receptor–flexible ligand docking protocol. J Comput Chem 2022; 43(2): 84-95.
[http://dx.doi.org/10.1002/jcc.26759] [PMID: 34741467]
[22]
Suh D, Schwartz R, Gupta PK, Zev S, Major DT, Im W. CHARMM-GUI EnzyDocker for protein–ligand docking of multiple reactive states along a reaction coordinate in enzymes. J Chem Theory Comput 2025; 21(4): 2118-28.
[http://dx.doi.org/10.1021/acs.jctc.4c01691] [PMID: 39950957]
[23]
Guterres H, Park SJ, Zhang H, Perone T, Kim J, Im W. CHARMM-GUI high-throughput simulator for efficient evaluation of protein–ligand interactions with different force fields. Protein Sci 2022; 31(9): 4413.
[http://dx.doi.org/10.1002/pro.4413]
[24]
Kong L, Park SJ, Im W. CHARMM-GUI PDB reader and manipulator: Covalent ligand modeling and simulation. J Mol Biol 2024; 436(17): 168554.
[http://dx.doi.org/10.1016/j.jmb.2024.168554] [PMID: 39237201]
[25]
Kumar A, MacKerell AD Jr. FFParam-v2.0: A comprehensive tool for charmm additive and drude polarizable force-field parameter optimization and validation. J Phys Chem B 2024; 128(18): 4385-95.
[http://dx.doi.org/10.1021/acs.jpcb.4c01314] [PMID: 38690986]
[26]
Allen C, Bureau HR, McGee TD Jr, Quirk S, Hernandez R. Benchmarking adaptive steered molecular dynamics (ASMD) on CHARMM force fields. ChemPhysChem 2022; 23(17): 202200175.
[http://dx.doi.org/10.1002/cphc.202200175] [PMID: 35594194]
[27]
dos Santos Nascimento IJ, de Moura RO. Molecular dynamics simulations in drug discovery. Mini Rev Med Chem 2024; 24(11): 1061-2.
[http://dx.doi.org/10.2174/138955752411240402134719] [PMID: 39004837]
[28]
Choi YK, Kern NR, Kim S, et al. CHARMM-GUI nanomaterial modeler for modeling and simulation of nanomaterial systems. J Chem Theory Comput 2022; 18(1): 479-93.
[http://dx.doi.org/10.1021/acs.jctc.1c00996] [PMID: 34871001]
[29]
Patel S, Mackerell AD Jr, Brooks CL III. CHARMM fluctuating charge force field for proteins: II Protein/solvent properties from molecular dynamics simulations using a nonadditive electrostatic model. J Comput Chem 2004; 25(12): 1504-14.
[http://dx.doi.org/10.1002/jcc.20077] [PMID: 15224394]
[30]
Bjelkmar P, Larsson P, Cuendet MA, Hess B, Lindahl E. Implementation of the CHARMM force field in GROMACS: Analysis of protein stability effects from correction maps, virtual interaction sites, and water models. J Chem Theory Comput 2010; 6(2): 459-66.
[http://dx.doi.org/10.1021/ct900549r] [PMID: 26617301]
[31]
Lama J, Buhidma Y, Fletcher EJR, Duty S. Animal models of Parkinson’s disease: A guide to selecting the optimal model for your research. Neuronal Signal 2021; 5(4): NS20210026.
[http://dx.doi.org/10.1042/NS20210026] [PMID: 34956652]
[32]
Lange S, Inal JM. Animal models of human disease. Int J Mol Sci 2023; 24(21): 15821.
[http://dx.doi.org/10.3390/ijms242115821] [PMID: 37958801]
[33]
Lee GH, Kim K, Jo W. Stress evaluation of mouse husbandry environments for improving laboratory animal welfare. Animals (Basel) 2023; 13(2): 249.
[http://dx.doi.org/10.3390/ani13020249] [PMID: 36670789]
[34]
Cho E, Walsh CA, D’Angelo-Gavrish NM, Wilson SR, Cirillo PA, Smith PC. Effects of housing density on reproductive performance, intracage ammonia, and welfare of mice continuously housed as breeders in standard mouse and rat caging. J Am Assoc Lab Anim Sci 2023; 62(2): 116-22.
[http://dx.doi.org/10.30802/AALAS-JAALAS-22-000069] [PMID: 36878483]
[35]
Ratuski AS, Weary DM. Environmental enrichment for rats and mice housed in laboratories: A metareview. Animals (Basel) 2022; 12(4): 414.
[http://dx.doi.org/10.3390/ani12040414] [PMID: 35203123]
[36]
Andersson M, Pernold K, Lilja N, Frias-Beneyto R, Ulfhake B. Longitudinal study of changes in ammonia, carbon dioxide, humidity and temperature in individually ventilated cages housing female and male c57bl/6n mice during consecutive cycles of weekly and bi-weekly cage changes. Animals 2024; 14(18): 2735.
[http://dx.doi.org/10.3390/ani14182735] [PMID: 39335324]
[37]
Ahmadi-Noorbakhsh S, Farajli Abbasi M, Ghasemi M, et al. Anesthesia and analgesia for common research models of adult mice. Lab Anim Res 2022; 38(1): 40.
[http://dx.doi.org/10.1186/s42826-022-00150-3] [PMID: 36514128]
[38]
Hidayat R, Wulandari P. Protocol for anesthesia animal model in biomedical study. Bioscientia Medicina. J Biomed Translat Res 2021; 5(7): 619-23.
[39]
Hickman DL. Minimal exposure times for irreversible euthanasia with carbon dioxide in mice and rats. J Am Assoc Lab Anim Sci 2022; 61(3): 283-6.
[http://dx.doi.org/10.30802/AALAS-JAALAS-21-000113] [PMID: 35414376]
[40]
Hedenqvist P. Laboratory animal analgesia, anesthesia, and euthanasia. Handbook of Laboratory Animal Science. Boca Raton, Florida: CRC Press 2021.
[http://dx.doi.org/10.1201/9780429439964-15]
[41]
Jacquez B, Choi H, Bird CW, Linsenbardt DN, Valenzuela CF. Characterization of motor function in mice developmentally exposed to ethanol using the Catwalk system: Comparison with the triple horizontal bar and rotarod tests. Behav Brain Res 2021; 396: 112885.
[http://dx.doi.org/10.1016/j.bbr.2020.112885] [PMID: 32860829]
[42]
Widjaja JH, Sloan DC, Hauger JA, Muntean BS. Customizable open-source rotating Rod (Rotarod) enables robust low-cost assessment of motor performance in mice. eNeuro 2023; 10(9): ENEURO.0123-23.2023.
[http://dx.doi.org/10.1523/ENEURO.0123-23.2023] [PMID: 37673671]
[43]
Shan HM, Maurer MA, Schwab ME. Four-parameter analysis in modified Rotarod test for detecting minor motor deficits in mice. BMC Biol 2023; 21(1): 177.
[http://dx.doi.org/10.1186/s12915-023-01679-y] [PMID: 37592249]
[44]
Waku I, Magalhães MS, Alves CO, de Oliveira AR. Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. Eur J Neurosci 2021; 53(11): 3743-67.
[http://dx.doi.org/10.1111/ejn.15222] [PMID: 33818841]
[45]
David AA, Oladele AA, Philip AO, et al. Neuroprotective Effects of Garcinia kola ethanol Seed Extract on Haloperidol-Induced Catalepsy in Mice. Trop J Nat Prod Res 2022; 6(2): 281-6.
[46]
Kumar N, James R, Sinha S, Kinra M, Anuranjana PV, Nandakumar K. Naringin exhibited Anti-Parkinsonian like effect against haloperidol-induced catalepsy in mice. Res J Pharm Tech 2021; 14(2): 662-6.
[http://dx.doi.org/10.5958/0974-360X.2021.00118.9]
[47]
Kirubakaran R. Equipments in experimental pharmacology. Introduction to Basics of Pharmacology and Toxicology. Lakshmanan M.ShewadeD.G.RajG.M. Singapore: Springer 2022; 3: pp. 77-100.
[http://dx.doi.org/10.1007/978-981-19-5343-9_6]
[48]
Rani M, Chhikara M, Rani R, Pawar N. Evaluation of antianxiety activity of Linalyl acetate in Swiss albino Mice. Ann Rom Soc Cell Biol 2022; 26(1): 3470-82.
[49]
Shukla D, Goel A, Mandal PK, et al. Glutathione depletion and concomitant elevation of susceptibility in patients with parkinson’s disease: State-of-the-art MR spectroscopy and neuropsychological study. ACS Chem Neurosci 2023; 14(24): 4383-94.
[http://dx.doi.org/10.1021/acschemneuro.3c00717] [PMID: 38050970]
[50]
Wang HL, Zhang J, Li YP, Dong L, Chen YZ. Potential use of glutathione as a treatment for Parkinson’s disease. Exp Ther Med 2020; 21(2): 125.
[http://dx.doi.org/10.3892/etm.2020.9557] [PMID: 33376507]
[51]
El Kodsi DN, Tokarew JM, Sengupta R, et al. Parkin coregulates glutathione metabolism in adult mammalian brain. Acta Neuropathol Commun 2023; 11(1): 19.
[http://dx.doi.org/10.1186/s40478-022-01488-4] [PMID: 36691076]
[52]
Wang Z, Wen H, Zheng C, et al. Synergistic co–cu dual-atom nanozyme with promoted catalase-like activity for parkinson’s disease treatment. ACS Appl Mater Interfaces 2025; 17(1): 583-93.
[http://dx.doi.org/10.1021/acsami.4c17416] [PMID: 39690140]
[53]
Alkholifi FK, Devi S, Aldawsari MF, et al. Effects of tiliroside and lisuride co-treatment on the PI3K/Akt signal pathway: Modulating neuroinflammation and apoptosis in Parkinson’s disease. Biomedicines 2023; 11(10): 2735.
[http://dx.doi.org/10.3390/biomedicines11102735] [PMID: 37893109]
[54]
Akhter N, Rafiq I, Jamil A, Chauhdary Z, Mustafa A, Nisar A. Neuroprotective effect of Thymus vulgaris on paraquat induced Parkinson’s disease. Biochem Biophys Res Commun 2025; 761: 151740.
[http://dx.doi.org/10.1016/j.bbrc.2025.151740] [PMID: 40188599]
[55]
Usama Ashhar M, Vyas P, Vohora D, et al. Amelioration of oxidative stress utilizing nanoemulsion loaded with bromocriptine and glutathione for the management of Parkinson’s disease. Int J Pharm 2022; 618: 121683.
[http://dx.doi.org/10.1016/j.ijpharm.2022.121683] [PMID: 35314276]
[56]
Roy A, Banerjee R, Choudhury S, et al. Novel inflammasome and oxidative modulators in Parkinson’s disease: A prospective study. Neurosci Lett 2022; 786: 136768.
[http://dx.doi.org/10.1016/j.neulet.2022.136768] [PMID: 35780939]
[57]
Alqurashi MM, Al-Abbasi FA, Afzal M, et al. Protective effect of sterubin against neurochemical and behavioral impairments in rotenone-induced Parkinson’s disease. Braz J Med Biol Res 2024; 57: 12829.
[http://dx.doi.org/10.1590/1414-431x2023e12829] [PMID: 38359270]
[58]
Ahmad MH, Fatima M, Ali M, Rizvi MA, Mondal AC. Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson’s disease. Neuropharmacology 2021; 201: 108831.
[http://dx.doi.org/10.1016/j.neuropharm.2021.108831] [PMID: 34655599]
[59]
Sharma N, Khurana N, Muthuraman A, Utreja P. Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson’s disease rat model. Eur J Pharmacol 2021; 903: 174112.
[http://dx.doi.org/10.1016/j.ejphar.2021.174112] [PMID: 33901458]
[60]
Anguchamy V, Muthuvel A. Enhancing the neuroprotective effect of squid outer skin astaxanthin against rotenone-induced neurotoxicity in in-vitro model for Parkinson’s disease. Food Chem Toxicol 2023; 178: 113846.
[http://dx.doi.org/10.1016/j.fct.2023.113846] [PMID: 37277017]
[61]
Homolak J, Joja M, Grabaric G, et al. The absence of gastrointestinal redox dyshomeostasis in the brain-first rat model of Parkinson’s disease induced by bilateral intrastriatal 6-hydroxydopamine. Mol Neurobiol 2024; 61(8): 5481-93.
[http://dx.doi.org/10.1007/s12035-023-03906-7] [PMID: 38200352]
[62]
Siddique YH, Naz F, Mantasha I, Shahid M. Lemongrass extract alleviates oxidative stress and delayed the loss of climbing ability in transgenic Drosophila model of Parkinson’s disease. Lett Drug Des Discov 2021; 18(10): 987-97.
[http://dx.doi.org/10.2174/1570180818666210413141434]
[63]
Park M, Ha J, Lee Y, Choi HS, Kim BS, Jeong YK. Low-moderate dose whole-brain γ-ray irradiation modulates the expressions of glial fibrillary acidic protein and intercellular adhesion molecule-1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine–induced Parkinson’s disease mouse model. Neurobiol Aging 2023; 132: 175-84.
[http://dx.doi.org/10.1016/j.neurobiolaging.2023.06.015] [PMID: 37837733]
[64]
Nairuz T, Sangwoo-Cho , Lee JH. Photobiomodulation therapy on brain: Pioneering an innovative approach to revolutionize cognitive dynamics. Cells 2024; 13(11): 966.
[http://dx.doi.org/10.3390/cells13110966] [PMID: 38891098]
[65]
Santos J, Quimque MT, Liman RA, et al. Computational and experimental assessments of magnolol as a neuroprotective agent and utilization of UiO-66 (Zr) as Its drug delivery system. ACS Omega 2021; 6(38): 24382-96.
[http://dx.doi.org/10.1021/acsomega.1c02555] [PMID: 34604621]
[66]
Okoye K, Hosseini S. Analysis of variance (ANOVA) in R: One-way and two-way ANOVA. R Programming: Statistical Data Analysis in Research. Singapore: Springer Nature 2024; pp. 187-209.
[http://dx.doi.org/10.1007/978-981-97-3385-9_9]
[67]
Wilcox R. One-way and two-way anova: Inferences about a robust, heteroscedastic measure of effect size. Methodology 2022; 18(1): 58-73.
[http://dx.doi.org/10.5964/meth.7769]
[68]
Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998; 395(6698): 137-43.
[http://dx.doi.org/10.1038/25931] [PMID: 9744270]
[69]
Becker G, Müller A, Braune S, et al. Early diagnosis of Parkinson’s disease. J Neurol 2002; 249(0): 1-, 40-48.
[http://dx.doi.org/10.1007/s00415-002-1309-9] [PMID: 12522572]
[70]
Leite Silva ABR, Gonçalves de Oliveira RW, Diógenes GP, et al. Premotor, nonmotor and motor symptoms of Parkinson’s Disease: A new clinical state of the art. Ageing Res Rev 2023; 84: 101834.
[http://dx.doi.org/10.1016/j.arr.2022.101834] [PMID: 36581178]
[71]
Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee. Neurology 2021; 97(20): 942-57.
[http://dx.doi.org/10.1212/WNL.0000000000012868] [PMID: 34782410]
[72]
Chua CY, Koh MRE, Chia NSY, et al. Subjective cognitive Complaints in early Parkinson’s disease patients with normal cognition are associated with affective symptoms. Parkinsonism Relat Disord 2021; 82: 24-8.
[http://dx.doi.org/10.1016/j.parkreldis.2020.11.013] [PMID: 33227684]
[73]
Kwon KY, Lee EJ, Lee M, Ju H, Im K. Impact of motor subtype on non-motor symptoms and fall-related features in patients with early PARKINSON’S disease. Geriatr Gerontol Int 2021; 21(5): 416-20.
[http://dx.doi.org/10.1111/ggi.14156] [PMID: 33780137]
[74]
Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79(4): 368-76.
[http://dx.doi.org/10.1136/jnnp.2007.131045] [PMID: 18344392]
[75]
Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 2009; 16(4): 450-6.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02514.x] [PMID: 19187262]
[76]
Parisi L, RaviChandran N, Manaog ML. Feature-driven machine learning to improve early diagnosis of Parkinson’s disease. Expert Syst Appl 2018; 110: 182-90.
[http://dx.doi.org/10.1016/j.eswa.2018.06.003]

Rights & Permissions Print Cite